Onxeo S.A. announced that it has received from the European Patent Office a notice of intent to grant a patent which strengthens the protection in Europe of AsiDNATM, its first-in-class inhibitor of tumor DNA repair in combination with PARP inhibitors (PARPi). This patent protects in particular the method of use of AsiDNATM in combination with PARP inhibitors in the treatment of certain cancers for which the DNA repair pathway via homologous recombination (HR) is not impaired or deficient, these HR-proficient cancers being mostly insensitive to treatment with PARP inhibitors. This patent will provide a term of protection until 2036. It completes the already robust set of patent families protecting AsiDNATM and its related compounds, alone or in combination. The DNA repair pathways, BRCA-dependent homologous recombination pathway and PARP pathway, are complementary and essential for tumor cell survival and proliferation. If one pathway is deficient (homologous recombination by BRCA mutation) and the other is blocked by a PARP inhibitor, the cell dies (synthetic lethality). PARPi have demonstrated a real clinical benefit 1, particularly in the treatment of ovarian cancer with BRCA mutations, but this benefit is much reduced, or even insignificant, when homologous recombination remains active in about 50% of patients. Extending the efficacy of PARP inhibitors to this important group would represent a major therapeutic opportunity for these patients whose options are currently limited.